Single Dose Study of MK-2214 in Healthy Japanese Participants

JRCT ID: jRCT2031220627

Registered date:09/02/2023

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Alzheimer's Disease
• Date of first enrollment: 17/03/2023
• Target sample size: 48
• Study type: Interventional

Intervention(s)

Single i.v. dosing
Panel A: MK-2214 700mg or Placebo
Panel B: MK-2214 2100mg or Placebo
Panel C and D: MK-2214 4200mg or Placebo

Outcome(s)

• Primary Outcome: Adverse event
• Secondary Outcome: AUC0-inf, AUC0-last, AUC0-140d, AUC0-28d, Cmax, Tmax, t1/2, CL and Vz

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: <= 75age old
• Gender: Both
• Include criteria: Healthy male or female aged 18 to 75 years old with BMI 18 to 30 kg/m2
• Exclude criteria: Has a history of clinically significant abnormalities or diseases

Related Information

• Primary Sponsor: Tanaka Yoshiyuki
• Secondary ID(s): Nil known